<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25777" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neuroblastoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahapatra</surname>
            <given-names>Sidharth</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Challagundla</surname>
            <given-names>Kishore B.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sidharth Mahapatra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kishore Challagundla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25777.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neuroblastoma (NB) is the most frequently-occurring extracranial childhood tumor. It is classified as an embryonal neuroendocrine tumor, originating from neural crest progenitor cells. Hence, it can occur anywhere along the sympathetic nervous system, including the superior cervical, paraspinal, and celiac ganglia; the majority arise in the adrenal glands. Due to the high variability in its presentation, clinical signs and symptoms at presentation can range from benign palpable mass with distension to major illness from substantial tumor spread. This activity reviews the cause, pathophysiology, and presentation of neuroblastoma and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of neuroblastoma.</p></list-item><list-item><p>Review the presentation of neuroblastoma.</p></list-item><list-item><p>Summarize the treatment options for neuroblastoma.</p></list-item><list-item><p>Explain modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by neuroblastoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25777&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25777">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25777.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Neuroblastoma (NB) is the most frequently-occurring extracranial childhood tumor. It is classified as an embryonal neuroendocrine tumor, originating from neural crest progenitor cells.<xref ref-type="bibr" rid="article-25777.r1">[1]</xref> Hence, it can occur anywhere along the sympathetic nervous system, including the superior cervical, paraspinal, and celiac ganglia; the majority arise in the adrenal glands.<xref ref-type="bibr" rid="article-25777.r2">[2]</xref> Due to the high variability in its presentation, clinical signs and symptoms at presentation can range from a benign palpable mass with distension to major illness from substantial tumor spread. Although overall increases in five-year event-free survival have been reported, subgroup-specific analysis of mortality has revealed discordance between the high cure rates for the more benign low-risk forms and little improvement in the high-risk groups.<xref ref-type="bibr" rid="article-25777.r3">[3]</xref><xref ref-type="bibr" rid="article-25777.r4">[4]</xref> Thus, the impetus for the development of targeted therapeutics in the intensive management of high-risk groups is strong.</p>
      </sec>
      <sec id="article-25777.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Risk factors for the acquisition of mutations in key genes leading to neuroblastoma&#x000a0;have yet to be identified, although exposures during conception and pregnancy are a topic of investigation.&#x000a0;Neuroblastoma can develop either sporadically or be transmitted in the germline. Most familial cases of neuroblastoma&#x000a0;occur due to the inheritance of highly penetrant mutations in either the <italic toggle="yes">ALK</italic> or <italic toggle="yes">PHOX2B</italic> genes.<xref ref-type="bibr" rid="article-25777.r2">[2]</xref>
<xref ref-type="bibr" rid="article-25777.r5">[5]</xref>&#x000a0;A small subset of familial NB demonstrates autosomal dominant inheritance.<xref ref-type="bibr" rid="article-25777.r6">[6]</xref> Although up to 15% of sporadic cases of neuroblastoma&#x000a0;arise from mutations in <italic toggle="yes">ALK</italic>, more common transforming mutations involve polymorphisms in <italic toggle="yes">BARD1</italic> (2q35), <italic toggle="yes">LIN28B</italic> (6q16.3), or <italic toggle="yes">FLJ22536</italic> (6p22.3). Cytogenetic aberrations can further include loss of chromosome 1p and 11q, copy number variation in 1q21, and gain of 17q.<xref ref-type="bibr" rid="article-25777.r1">[1]</xref><xref ref-type="bibr" rid="article-25777.r7">[7]</xref><xref ref-type="bibr" rid="article-25777.r8">[8]</xref><xref ref-type="bibr" rid="article-25777.r9">[9]</xref>&#x000a0;Notably, amplification of MYCN oncogene is seen in approximately 25% of patients and is associated with the poorest prognosis; 17q gain and 1p loss correlate with MYCN amplification.<xref ref-type="bibr" rid="article-25777.r1">[1]</xref><xref ref-type="bibr" rid="article-25777.r10">[10]</xref></p>
      </sec>
      <sec id="article-25777.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months.<xref ref-type="bibr" rid="article-25777.r11">[11]</xref> It accounts for 15% of pediatric cancer-related deaths.<xref ref-type="bibr" rid="article-25777.r12">[12]</xref> The annual incidence of neuroblastoma in the United States is approximately 650 cases, i.e., 10.2 per million children (65 per million infants), with little change (0.4%)&#x000a0;over time.<xref ref-type="bibr" rid="article-25777.r2">[2]</xref> While an overall improvement in five-year mortality has been noted between 1975 through 2005, subgroup-specific mortality paints a different picture.</p>
      </sec>
      <sec id="article-25777.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Many biological markers of neuroblastoma have been discovered, of which the most important is MYCN. This oncogene is overexpressed in nearly 25% of patients with neuroblastoma. The gene is also commonly found in patients with advanced cancer. Patients with the MYCN gene tend to have rapid progression of cancer and poor outcomes. On the other hand, expression of the H-Ras gene is associated with low stage disease.</p>
        <p>The DNA index is also used to assess response to treatment. Those with a DNA index of more than 1 tend to show a good response to doxorubicin and cyclophosphamide compared to those with an index of less than 1. Other biological markers linked to poor prognosis include lack of expression of glycoprotein CD 44 and elevated levels of telomerase RNA. Other markers linked to poor prognosis include elevated levels of LDH, serum ferritin, and serum neuron-specific enolase.</p>
        <p>Close to 90% of patients have elevations in vanillyl mandelic acid and homovanillic acid in the urine. In Japan, mass screening using urinary catecholamines has been shown to lower deaths from high-risk neuroblastomas.</p>
        <p>Neuroblastomas can develop in the adrenal gland (most common), paraspinal ganglia, and less often in the thorax, pelvis, and cervical areas. Infants commonly present with neck or thoracic masses, whereas older children tend to present with abdominal masses.</p>
        <p>The symptoms are chiefly due to the mass of the lesion, which increases abdominal girth and causes pain. Lesions in the spinal canal can present with neurological deficits.</p>
      </sec>
      <sec id="article-25777.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathology will reveal small round blue cells with clustering of cells in the connective tissue and the presence of pseudorosettes. These pseudorosettes are only seen in 10%-15% of cases.</p>
      </sec>
      <sec id="article-25777.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Given the wide areas populated by neural crest cells, neuroblastoma can present in the neck, chest, abdomen, or pelvis. With the most frequent site of origin being the adrenal medulla, patients often present with a solid abdominal mass. With the involvement of the superior cervical ganglia, aside from a neck mass, Horner syndrome (ptosis, miosis, anhydrosis) can be observed. If the tumor involves the spinal cord, cord compression, or paralysis may be seen. Furthermore, tumor behavior can range from spontaneous regression to widespread dissemination at presentation. With over half of all neuroblastoma&#x000a0;patients having hematogenous spread at diagnosis, the disease can involve the bone and bone marrow (56% and 71%, respectively), followed by lymph nodes (31%), and lungs (3%). Non-specific clinical signs include fever, weight loss, and fatigue. Thus, signs and symptoms, which can range from an asymptomatic palpable mass to significant critical illness, are highly variable and dependent upon factors now linked with prognosis.</p>
        <p>Hypertension is rare and is often caused by compression of the renal artery rather than the catecholamine excess.</p>
        <p>Chronic diarrhea due to the secretion of vasoactive intestinal&#x000a0;peptide&#x000a0;may be the initial presentation.</p>
        <p>When the bone is involved, pain and a limp may be present. In addition, bone metastases may present with pathological fractures.</p>
        <p>Thoracic lesions may present with Horner syndrome.</p>
        <p>In rare cases, the patient may present with myoclonus and opsoclonus. These patients tend to have localized disease and good outcomes. However, the neurological deficit can be disabling.</p>
      </sec>
      <sec id="article-25777.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Clinical Evaluation</p>
        <p>Diagnostic evaluation relies not only on a careful history and physical, but also on biochemical, histologic, and radiographic analyses. Laboratory studies should include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>CBC</p>
          </list-item>
          <list-item>
            <p>Renal function</p>
          </list-item>
          <list-item>
            <p>Liver function</p>
          </list-item>
          <list-item>
            <p>Electrolytes</p>
          </list-item>
          <list-item>
            <p>LDH</p>
          </list-item>
        </list>
        <p>Histologic confirmation is required to establish a diagnosis of&#x000a0;neuroblastoma. Histologically, small round pale blue cells, known as Homer-Wright pseudorosettes, can be seen; these are similarly seen in Wilm's tumor and Ewing sarcoma, leading to their common group categorization as small blue cell tumors.<xref ref-type="bibr" rid="article-25777.r1">[1]</xref> If a biopsy sample is tumor-positive, DNA ploidy and MYCN gene status are further evaluated. Since neuroblastoma cells originate from neural crest cells destined to differentiate into sympathetic peripheral neurons, cells often produce catecholamines; break-down products of these catecholamines are homovanillic acid (HVA) and vanillylmandelic acid (VMA). Thus, in over 90% of neuroblastoma, elevation in these catecholamine breakdown products in urine is diagnostic.<xref ref-type="bibr" rid="article-25777.r13">[13]</xref></p>
        <p>Preliminary imaging is preferentially conducted with MRI for good resolution and surgical excision planning. Further exploiting sympathetic neuronal uptake of mIBG (metaiodobenzylguanidine), due to its analogous nature to norepinephrine, the extent of&#x000a0;neuroblastoma&#x000a0;metastasis can be delineated with an mIBG scan with high accuracy and quality.<xref ref-type="bibr" rid="article-25777.r14">[14]</xref> To complete tumor staging, bone marrow biopsies are required.<xref ref-type="bibr" rid="article-25777.r1">[1]</xref>&#x000a0;Of note, common paraneoplastic conditions associated with&#x000a0;neuroblastoma&#x000a0;include opsoclonus-myoclonus syndrome and intractable secretory diarrhea due to vasoactive intestinal peptide (VIP) secretion.<xref ref-type="bibr" rid="article-25777.r15">[15]</xref><xref ref-type="bibr" rid="article-25777.r16">[16]</xref></p>
        <p>CT scan of the abdomen and chest are recommended to look for calcifications and metastatic lesions.</p>
        <p>MRI is the spine is required if cord compression and Horner syndrome are suspected.</p>
        <p>Skeletal surveys may help assess the presence of metastatic lesions.</p>
        <p>Baseline ECG and echocardiogram are necessary. Baseline hearing is recommended before initiating cisplatinum treatment.</p>
      </sec>
      <sec id="article-25777.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Given the heterogeneity in tumor location, grade, and stage at diagnosis, treatment modalities include simple observation, surgical resection, chemotherapy, radiation therapy, stem cell transplantation, and immunotherapy. Patients with low-risk NB have localized tumors, some (infants) with a high propensity for spontaneous tumor regression.<xref ref-type="bibr" rid="article-25777.r17">[17]</xref> Thus, children with small tumors (less than 5 cm) can be observed with imaging done every six to 12 weeks to monitor tumor growth, thus avoiding surgery in the young infant altogether.<xref ref-type="bibr" rid="article-25777.r1">[1]</xref></p>
        <p>For larger, localized tumors, in patients' past infancy, surgical resection is pursued. For patients younger than 18 months of age, the observational approach is currently&#x000a0;under international investigation by COG (NCT02176967) and SIOPEN (NCT01728155) cooperative groups. For children who present with symptoms, limited chemotherapy is given without surgical palliation or radiation therapy.<xref ref-type="bibr" rid="article-25777.r1">[1]</xref></p>
        <p>The intermediate-risk group presents with localized metastasis, i.e., to the lymph node or bone marrow (in infants). They are usually managed with chemotherapy alone and possible surgical resection if able.<xref ref-type="bibr" rid="article-25777.r18">[18]</xref></p>
        <p>The high-risk group has the worst prognosis and presents with widespread metastatic disease to the bone marrow, bone, lungs, and liver. They receive induction chemotherapy to reduce tumor burden at both the primary and metastatic locations, followed by maximal surgical resection, followed by myeloablative chemotherapy and stem-cell transplantation. After that, patients are managed on a combination of maintenance chemotherapy and immunotherapy.<xref ref-type="bibr" rid="article-25777.r19">[19]</xref> A monoclonal antibody, dinutuximab that attaches to a carbohydrate molecule (GD2) on the surface of many neuroblastoma cells, is being used as&#x000a0;an immunotherapy drug for neuroblastoma treatment. Dinutuximab treatment is reported to improve the two-year event-free survival of high-risk neuroblastoma patients from 46% to 66%.<xref ref-type="bibr" rid="article-25777.r20">[20]</xref></p>
        <p>Surgery plays a vital role in the treatment of neuroblastoma. For localized disease, one can obtain a cure with surgery. Sometimes surgery is needed to establish a diagnosis. Second look surgery after chemotherapy is often done for debulking purposes.</p>
      </sec>
      <sec id="article-25777.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Dermoid cyst</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ewings sarcoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Germ cell tumour</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hepatoblastoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infantile fibromatosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lymphoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rhabdomyosarcoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Small round cell sarcoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wilm&#x02019;s syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25777.s11" sec-type="Staging">
        <title>Staging</title>
        <p>The International Neuroblastoma Staging System (INSS) based on surgical resection is used to stage neuroblastomas in the United States.</p>
        <p>Stage 1:</p>
        <list list-type="bullet">
          <list-item>
            <p>A localized lesion with complete gross excision. There may be microscopic residual disease</p>
          </list-item>
          <list-item>
            <p>Ipsilateral lymph nodes are negative for cancer</p>
          </list-item>
        </list>
        <p>Stage 2:</p>
        <list list-type="bullet">
          <list-item>
            <p>Localized tumor with obvious gross tumor not completely excised</p>
          </list-item>
          <list-item>
            <p>Ipsilateral lymph nodes are negative for cancer</p>
          </list-item>
        </list>
        <p>Stage 2B</p>
        <list list-type="bullet">
          <list-item>
            <p>Localized tumor with complete gross excision but ipsilateral lymph nodes are positive for tumor</p>
          </list-item>
          <list-item>
            <p>Enlarged contralateral lymph nodes are negative for cancer</p>
          </list-item>
        </list>
        <p>Stage 3:</p>
        <list list-type="bullet">
          <list-item>
            <p>Unresectable cancer that has crossed the midline, there is regional lymph node involvement</p>
          </list-item>
          <list-item>
            <p>A localized unilateral lesion with positive contralateral lymph nodes</p>
          </list-item>
        </list>
        <p>Stage 4: Any primary lesion that has spread to distant lymph nodes, liver, bone marrow or skin</p>
        <p>Stage 4s:</p>
        <list list-type="bullet">
          <list-item>
            <p>Localized primary tumor with spread limited to liver, skin or bone marrow</p>
          </list-item>
          <list-item>
            <p>Limited to infants</p>
          </list-item>
        </list>
        <p>
<bold>Subgroup Classification</bold>
</p>
        <p>The widespread variability in&#x000a0;neuroblastoma&#x000a0;tumor behavior is linked to multiple factors now linked with patient prognosis. Classic prognostic categorization by Children&#x02019;s Oncology Group (COG) divides patients into four groups based on patient age, post-surgical stage, MYCN amplification, histology, and DNA ploidy <xref ref-type="bibr" rid="article-25777.r3">[3]</xref>:</p>
        <list list-type="order">
          <list-item>
            <p>Low risk: localized tumor only, greater than 90% survival</p>
          </list-item>
          <list-item>
            <p>Intermediate risk: localized tumor with regional extension and/or metastases to bone and bone marrow, 90% to 95% survival</p>
          </list-item>
          <list-item>
            <p>High risk: widely disseminated disease (excluding infants), 40% to 50% survival</p>
          </list-item>
          <list-item>
            <p>Tumor stage 4S: widely disseminated disease in infants, greater than 90% survival due to spontaneous regression of the tumor.</p>
          </list-item>
        </list>
        <p>However, COG classification of&#x000a0;neuroblastoma&#x000a0;has differed from the European SIOPEN and other cooperative groups. In 2004, the International Neuroblastoma Risk Group (INRG), a task force of pediatric&#x000a0;neuroblastoma&#x000a0;experts worldwide, met with the primary aim of developing a consensus approach to neuroblastoma risk stratification pre-treatment.<xref ref-type="bibr" rid="article-25777.r21">[21]</xref> Using patient age, tumor stage, tumor grade, and differentiation, tumor histology, MYCN amplification, cytogenetic aberrations in 11q, and DNA ploidy, the group defined 16 pre-treatment groups broadly divisible into four prognostic subgroups based on five-year event-free survival (EFS):</p>
        <list list-type="order">
          <list-item>
            <p>Very low risk: five-year event-free survival (EFS) greater than 85%</p>
          </list-item>
          <list-item>
            <p>Low risk: five-year EFS 75% to 85%</p>
          </list-item>
          <list-item>
            <p>Intermediate risk: five-year EFS 50% to 75%</p>
          </list-item>
          <list-item>
            <p>High risk: five-year EFS less than 50%</p>
          </list-item>
        </list>
        <p>Over 50% of newly diagnosed&#x000a0;neuroblastoma&#x000a0;are very-low or low-risk.<xref ref-type="bibr" rid="article-25777.r21">[21]</xref> Negative prognostic markers include age older than 18 months, metastasis at diagnosis, and presence of MYCN amplification, 1p loss, 11q loss, 17q gain, or DNA copy number alterations.<xref ref-type="bibr" rid="article-25777.r1">[1]</xref><xref ref-type="bibr" rid="article-25777.r21">[21]</xref></p>
      </sec>
      <sec id="article-25777.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Neuroblastoma is a rare abdominal tumor in young children. However, if the diagnosis is missed, the tumor is fatal. Hence, the diagnosis and treatment of neuroblastoma are best managed by an interprofessional team that includes a pediatrician, a pediatric surgeon, oncologist, radiation therapist, social workers, pharmacist, dietitian, and specialty care nurses. A team dedicated to childhood cancers is vital as these patients have special needs. All cancer treatments can stunt growth, and hence, a dietitian should be involved early in the care.</p>
        <p>The tumor may occur anywhere along the sympathetic chain and can be mistaken for a Wilms&#x000a0;tumor. Oncologic pharmacists assist in the formulation of chemotherapy, check for drug-drug interactions, and provide family and patient education. Oncology nurse practitioners and nurses play a vital role in patient care and the education of the family. Occupation therapy is necessary as some children may develop neurological deficits that may impair motor function. A positive environment is essential to ensure that the child thrives in this difficult situation. Team members should openly communicate with each other to improve their care. [Level 5]</p>
        <p>Over the past decade, the survival of these patients has slightly improved for early-stage lesions, but for late stages, the survival is abysmal.&#x000a0;Thus, the impetus for the development of targeted therapeutics in the intensive management of high-risk groups is strong.<xref ref-type="bibr" rid="article-25777.r22">[22]</xref><xref ref-type="bibr" rid="article-25777.r23">[23]</xref></p>
      </sec>
      <sec id="article-25777.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25777&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25777">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/neuroblastoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25777">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25777/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25777">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25777.s14">
        <title>References</title>
        <ref id="article-25777.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matthay</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schleiermacher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nakagawara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mackall</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Diller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Neuroblastoma.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2016</year>
            <month>Nov</month>
            <day>10</day>
            <volume>2</volume>
            <fpage>16078</fpage>
            <pub-id pub-id-type="pmid">27830764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in neuroblastoma.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Jun</month>
            <day>10</day>
            <volume>362</volume>
            <issue>23</issue>
            <fpage>2202</fpage>
            <page-range>2202-11</page-range>
            <pub-id pub-id-type="pmid">20558371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hogarty</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Bagatell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Neuroblastoma.</article-title>
            <source>Lancet</source>
            <year>2007</year>
            <month>Jun</month>
            <day>23</day>
            <volume>369</volume>
            <issue>9579</issue>
            <fpage>2106</fpage>
            <page-range>2106-20</page-range>
            <pub-id pub-id-type="pmid">17586306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linabery</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999.</article-title>
            <source>Cancer</source>
            <year>2008</year>
            <month>Nov</month>
            <day>01</day>
            <volume>113</volume>
            <issue>9</issue>
            <fpage>2575</fpage>
            <page-range>2575-96</page-range>
            <pub-id pub-id-type="pmid">18837040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moss&#x000e9;</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Laudenslager</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Attiyeh</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Laquaglia</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sennett</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Perri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Laureys</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Speleman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hakonarson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Torkamani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schork</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Brodeur</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Tonini</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Rappaport</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Identification of ALK as a major familial neuroblastoma predisposition gene.</article-title>
            <source>Nature</source>
            <year>2008</year>
            <month>Oct</month>
            <day>16</day>
            <volume>455</volume>
            <issue>7215</issue>
            <fpage>930</fpage>
            <page-range>930-5</page-range>
            <pub-id pub-id-type="pmid">18724359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knudson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Strong</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Mutation and cancer: neuroblastoma and pheochromocytoma.</article-title>
            <source>Am J Hum Genet</source>
            <year>1972</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>514</fpage>
            <page-range>514-32</page-range>
            <pub-id pub-id-type="pmid">4340974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mosse</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Bradfield</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Monni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Asgharzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Attiyeh</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Diskin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Laudenslager</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Glessner</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Frackelton</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Casalunovo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eckert</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Capasso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rappaport</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>McConville</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Devoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hakonarson</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Jun</month>
            <day>12</day>
            <volume>358</volume>
            <issue>24</issue>
            <fpage>2585</fpage>
            <page-range>2585-93</page-range>
            <pub-id pub-id-type="pmid">18463370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capasso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Asgharzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Glessner</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Attiyeh</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Mosse</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Diskin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bosse</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laudenslager</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bradfield</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Jagannathan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McConville</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rappaport</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hakonarson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.</article-title>
            <source>Nat Genet</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>718</fpage>
            <page-range>718-23</page-range>
            <pub-id pub-id-type="pmid">19412175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diskin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Capasso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schnepp</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Attiyeh</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jagannathan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Latorre</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Iolascon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hakonarson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Devoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.</article-title>
            <source>Nat Genet</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>10</issue>
            <fpage>1126</fpage>
            <page-range>1126-30</page-range>
            <pub-id pub-id-type="pmid">22941191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heukamp</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Thor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schramm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Preter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kumps</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Wilde</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Odersky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peifer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lindner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spruessel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pattyn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mestdagh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Menten</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kuhfittig-Kulle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>K&#x000fc;nkele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Meder</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ullrich</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Schulte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vandesompele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Speleman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>B&#x000fc;ttner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eggert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schulte</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.</article-title>
            <source>Sci Transl Med</source>
            <year>2012</year>
            <month>Jul</month>
            <day>04</day>
            <volume>4</volume>
            <issue>141</issue>
            <fpage>141ra91</fpage>
            <pub-id pub-id-type="pmid">22764207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Castleberry</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Matthay</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Look</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thorner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brodeur</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Sep</month>
            <day>20</day>
            <volume>23</volume>
            <issue>27</issue>
            <fpage>6459</fpage>
            <page-range>6459-65</page-range>
            <pub-id pub-id-type="pmid">16116153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Althoff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beckers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nortmeyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Spr&#x000fc;ssel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lindner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Preter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Florin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heukamp</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Klein-Hitpass</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Astrahantseff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kumps</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Speleman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eggert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Westermann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schramm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schulte</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.</article-title>
            <source>Oncogene</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>26</issue>
            <fpage>3357</fpage>
            <page-range>3357-68</page-range>
            <pub-id pub-id-type="pmid">25174395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LaBrosse</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Com-Nougu&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zucker</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Comoy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bohuon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lemerle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schweisguth</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors.</article-title>
            <source>Cancer Res</source>
            <year>1980</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>1995</fpage>
            <page-range>1995-2001</page-range>
            <pub-id pub-id-type="pmid">7371035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vik</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Pfluger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kadota</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Castel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tulchinsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farto</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Heiba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Serafini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tumeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khutoryansky</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>(123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>52</volume>
            <issue>7</issue>
            <fpage>784</fpage>
            <page-range>784-90</page-range>
            <pub-id pub-id-type="pmid">19185008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Holbrook</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>McDaniel</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Buntain</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Crist</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Vasoactive intestinal peptide secreting tumors of childhood.</article-title>
            <source>Am J Dis Child</source>
            <year>1980</year>
            <month>Jan</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-4</page-range>
            <pub-id pub-id-type="pmid">6101297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunklaus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pohl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zuberi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>de Sousa</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome.</article-title>
            <source>Arch Dis Child</source>
            <year>2012</year>
            <month>May</month>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>461</fpage>
            <page-range>461-3</page-range>
            <pub-id pub-id-type="pmid">21460401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matthay</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Stage 4S neuroblastoma: what makes it special?</article-title>
            <source>J Clin Oncol</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>2003</fpage>
            <page-range>2003-6</page-range>
            <pub-id pub-id-type="pmid">9626196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Buxton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stram</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Castleberry</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shamberger</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Look</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Matthay</surname>
                <given-names>KK</given-names>
              </name>
              <collab>Children&#x02019;s Oncology Group</collab>
            </person-group>
            <article-title>Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Sep</month>
            <day>30</day>
            <volume>363</volume>
            <issue>14</issue>
            <fpage>1313</fpage>
            <page-range>1313-23</page-range>
            <pub-id pub-id-type="pmid">20879880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bagatell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Mattay</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Hogarty</surname>
                <given-names>M</given-names>
              </name>
              <collab>COG Neuroblastoma Committee</collab>
            </person-group>
            <article-title>Children's Oncology Group's 2013 blueprint for research: neuroblastoma.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>985</fpage>
            <page-range>985-93</page-range>
            <pub-id pub-id-type="pmid">23255319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gilman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ozkaynak</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Kreissman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Villablanca</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Matthay</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Buxton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reisfeld</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gillies</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sondel</surname>
                <given-names>PM</given-names>
              </name>
              <collab>Children's Oncology Group</collab>
            </person-group>
            <article-title>Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Sep</month>
            <day>30</day>
            <volume>363</volume>
            <issue>14</issue>
            <fpage>1324</fpage>
            <page-range>1324-34</page-range>
            <pub-id pub-id-type="pmid">20879881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohn</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Monclair</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ambros</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Brodeur</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Faldum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hero</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Iehara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Machin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mosseri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Garaventa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Matthay</surname>
                <given-names>KK</given-names>
              </name>
              <collab>INRG Task Force</collab>
            </person-group>
            <article-title>The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Jan</month>
            <day>10</day>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>289</fpage>
            <page-range>289-97</page-range>
            <pub-id pub-id-type="pmid">19047291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zage</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Novel Therapies for Relapsed and Refractory Neuroblastoma.</article-title>
            <source>Children (Basel)</source>
            <year>2018</year>
            <month>Oct</month>
            <day>31</day>
            <volume>5</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">30384486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25777.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bansal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Totadri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chinnaswamy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Agarwala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Laskar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rath</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Bakhshi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of Neuroblastoma: ICMR Consensus Document.</article-title>
            <source>Indian J Pediatr</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>84</volume>
            <issue>6</issue>
            <fpage>446</fpage>
            <page-range>446-455</page-range>
            <pub-id pub-id-type="pmid">28367616</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
